Literature DB >> 6926770

Experience with mebendazole in the treatment of inoperable hydatid disease in England.

A D Bryceson, A G Cowie, C Macleod, S White, D Edwards, J D Smyth, D P McManus.   

Abstract

Eleven heterogeneous patients with inoperable hydatid disease were treated with high doses of oral mebendazole, up to 200 mg/kg/day for 16 to 48 weeks. Toxicity was not encountered. Despite careful assessment it proved difficult critically to evaluate the efficacy of mebendazole. In four patients chemotherapy appeared to have been at least partially successful and success seems to have correlated with serum levels in excess of 100 ng/ml one to three hours after dosage. The problems of assessment are discussed and the need for controlled trials of mebendazole in hydatid disease are stressed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6926770     DOI: 10.1016/0035-9203(82)90151-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

1.  Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions.

Authors:  P J Luder; B Siffert; F Witassek; F Meister; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

Authors:  Ren-Yuan Bai; Verena Staedtke; Colette M Aprhys; Gary L Gallia; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2011-07-15       Impact factor: 12.300

Review 3.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

4.  Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis.

Authors:  Moein Eskandari; Fereshteh Asgharzadeh; Mohammad Mostafa Askarnia-Faal; Hamideh Naimi; Amir Avan; Mitra Ahadi; Hassan Vossoughinia; Masoumeh Gharib; Atena Soleimani; Niloufar Naghibzadeh; Gordon Ferns; Mikhail Ryzhikov; Majid Khazaei; Seyed Mahdi Hassanian
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

5.  Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens.

Authors:  P J Luder; F Witassek; K Weigand; J Eckert; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Albendazole treatment of pulmonary hydatid cysts in naturally infected sheep: a study with relevance to the treatment of hydatid cysts in man.

Authors:  D L Morris; M J Clarkson; M F Stallbaumer; J Pritchard; R S Jones; J B Chinnery
Journal:  Thorax       Date:  1985-06       Impact factor: 9.139

7.  Albendazole in the treatment of hydatid disease.

Authors:  A Rahemtulla; A D Bryceson; D P McManus; D S Ellis
Journal:  J R Soc Med       Date:  1987-02       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.